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IETRODUCTION
Five years have elapsed since Dm1agk (19)
announced that he had found that prontosil had an
elective action against experimental streptococcal infections in mice and rabbits.

At the conclusion of this

interesting report he says, "Prontosil zeigt
ar.i

eine bisher

infizierte Tier nich beabachtete Streptokokkemvirkung.

Es gelingt, streptokokken infizierte MB.use, die unbehandelt innerhalb von 24 Stunden nach der Inferktion
eingelen, durch subcutane und perorale Prontosilsgaben
am. Leben zu erhalten.
~·virkung

Prontosil zeight eine elektive

bei der Streptokokkensepsis der r..fause".

In

carrying out his experiments he observed that prontosil
vJas not effective in vitro in preventing the growth or
killing cultures of streptococci.

He

di~

not consider

the drug toxic for he observed no signs of toxicity while
he was testing the efficacy of the drug in conbatting
staphylococcal and streptococcal infections in laboratory
anirn.als.
His v10rk was confiri.lled durinc: the same year in
France and later in 1935 Trefouel, Trefouel, Nitti, and
Bovet (100) found that para-amino-benzene sulfonamide,
the nucleus of the prontosils,was the active principle
by demonstrating that it is effective in controlling
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and curing experimental streptococcal infections in
animals.
Interest in these new chemicals became
actively stimulated on the continent und new cheir.cicals
with the para-amino-benzene sulfonamide nucleus vrnre
synthesized.

Lore experimental vrnrk on experimentally

infected animals was carried on, and the clinical use
of the drug increased.
The medical professions both in .America and
England were apparently unaware of the fact that an
important group of 6.rugs had been found to have extraordinary power in curing both experin:ental and clinical
streptococcal infections.

This is explained by the

fact that people naturHlly pay more attention to the
journals written in their own tonfue.

In addition to

this, the drugs were difficult to obtain in large
enough quantities to carry on any sicnificant work
because .American manufacturers had not yet perfected
suitable methods of synthesis to make available cheap
supplies of these drugs to investigators.
This unawareness, however, came to an end
after Colebrook and Kenny (13) and Buttle, et al, (11)
of Zngland,and Long and Bliss (60) made their renorts
concerning the effects of this group of drugs in 1936.
Since that time, the para-amino-benzene sulfonarrlide
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(sulfanilamide) group of C.rugs has

been very widely used

for treatine: both clinical and experimental infections.
Clinically and

experir~entally

tlley have been ehJ)loyed

for practically every known infection.

It is no wonder

that the statement is so often made that patients are
first treated vJi th sulfanilamicle and if' this has no
effect upon the course of the illness a history of

t~e

illness is obtained and a physical examiEation of the
patient is r1ade to discover the nature of the
coEplaint.

patient's

\Ji th such widespread use, both the beneficial

and deleterious effects of these substances could be
observed repeatedly.
These drugs have, without doubt, brought about
a wonderful advance in the treatment of bacterial infections.

In the case of' such substances, it is relatively

easy to become too enthusiastic over their effect and
ascribe to them the properties of a cure-all.

That

these substances have been found to have toxic effects
was not unanticipated since their nucleus is the benzene
ring with an arnino-group attached.

Such drugs have long

been known to be responsible for toxic effects upon ·the
blood picture and hematopoietic tissue.
In conparing the incidence of serious toxic
effects of the drug upon patients to those cases in
which no serious toxic changes occur, it is apparent

-
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that the percentage is small.

Due to the fact that the

drugs do have toxic effects should discourage their
promiscuous use in conditions where there is no real
indication for their use.

Their use, however, should

not be neglected in those cases in which it has been
proved th&t they are curative and beneficial, e.g.,
streptococcal, meningococcal, gonococcal, and pneurnococcal infections.
One of the nost interesting toxic effects is
the change which occurs in the blood picture of both
animals and patients given these Grugs.

Our interest

has been stimulated to some extent by the results
obtained in a few aninal experirr_ients at the University
of Nebraska (64) and also by the interesting reports
of blood dyscrasias

which have been incJ:·easeing ever

since the reports by Young (108) and Jennings c:.nd
Southwell-Sander (46) have been published.

In this

thesis a brief review is being made of agranulocytosis
and hemolytic anemia associated with the administration
of the drugs of the para-amino-benzene sulf onanide
group.
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.1hen Plw-_rier ( 77) reported in A1Jril, 1937, a

1

death due to leucopenia follovJine; treritrn.ent of subacute
bacterial endocar ii tis

by sulfanilamide, the experimental

production of blood changes produced by giving the
drug to experimental animals had not yet been accomplished.
Hawking (36) was unable to produce blood changes.
M1,rshall, et al, ( 69) published their work concerning
the toxicity of sulfanilamide in January 1938.

They

had fed 0. 2 grarns of sulfanilamide per kilogram to two
dogs for two months and had not found any change in
either the red cell, white blood cell, or in differential blood cell counts.

Large doses of sulfanilamide

were given to two dogs and four rabbits to determine
whether sulfanilamide affected the blood count v1hen
given in larse doses in a few days time.

These doses

ranged from 3.5 to 6 grams of the drug per kilogram
in 2 to 5 days tiroe.
was observed.

No effect upon the blood picture

Hagercan (33) gave 20 grams of sulfanila-

mide to a group of mice in 14 days time.

Since he found

that the spleens of these mice had much hemosiderin
deposit and tJ:at the eosinophils of the bone marrow
had increased, he suggested that the drug was able to
destroy red blood cells and cause an allergic response
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of the bone marrow.

Finkelstone and Sayliss (26)

noticed abnormal erythrocytes and nucleated red blood
cells in the blood of rabbi ts to which he fed 1. 2 graL'.S
each day.
Domagk ( 19) vvas unable to produce any changes
in the blood of experimental anir<ials with prontosil and
neo-prontosil.

In 1937 he (20) found that sulfanilyl

Eulfanilamide and various derivations of that drug were
able to cause various changes both in the white and
blood cell picture.

These changes were inconsistent as

far as the white cells were concerned.

The mono-methyl

derivative of sulfanilyl sulfanilamide caused the red
blood cell count to drop when given to laboratory animals.
Bone marrow studies were not made to determine the
reaction of the bone marrow to the drug.
Kreutzman and CaTr (57) gave 8 rabbits doses
of )rontosil for a period of 21 days.

The dosage was

slightly higher than the recornnended. dose.

The peri-

pheral blood counts did not consistently change throughout the exi)eriment but the red blood cell counts
incceased from 10 to 157b after the drug had been discontinued.

Spleens were moderately congested and the

single lobe eosinophils of the bone marrow were increased.
These findings were interpreted to be suggestive of a
mild bone marrow derre::sion caused by the continued

-
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administration of prontosil.
Vlhen '!Jhi tby ( 103) introduced sulf'apyridine
he thought that it ·would produce fewer toxic effects
than sulfanilamide.

V!ien (104) gave 0.25 mgs. per cram

of sulfapyridine to four rats for 14 days and 0.5 rags.
per gram to another group of four rats for 2 weeks.

He

used the same size dose of sulfanilamide for tv10 other
groups of rabbi ts for the sarie length of time.

Two

blood count'.::3 were made each week and no changes were
found in the peripheral blood picture.

Ho changes in

the blooc'1. pictures were found in cats given 1 gram of
sulfapyridine in ? days or in dogs given an identical
dose.

When he fed larger doses of sulfanilamide and

sulfapyridine, 1.5 to 3 mgs. per gram, to rats for
15 days, he found that those animals receiving sulfa-

nilarnide became anenic, had an
urinary porphyrin

inc,~·eased

amount of

output, but those that had received

sulfapyridine did not develop such chances.
During 1932> some of the effects of both small
doses of sulfanilamide given over a period of five
weeks and large doses given to rabbits were observed at
the Nebraska University College of

~·.=edicine

( 64)

15 rabbi ts were given 4 grar1s of sulfanilamide per kilo-

gram in a 24 hour period.

At the end of the sixth day

after the initial dose 13 rabbits were dead.
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The two

remaini~g

rabbits were killed.

The red and white blood

cell counts showed no consistent chance.

The

differential counts shifted to the left anc' the reticulocyte counts increased.
bone

marro~

Counts and studies made of the

stained by the panoptic stein revealed no

significant alterations.

Bone marrow counts of 8 normal

rabbits were made in order to have a basis of comnarison
f

o:!'.' the bone marrow counts nade on the marrow from the

experimental animals.
of sul:t'anilar:1icle
rabbits.

VJe

In

studyin~

the chronic effects

made observations on tvvo groups of

One group of four received daily doses of

sulfanilamide, 1.0 grmn. per 9 kilograns oi' vveight, for
a ueriod of 35 days.

The other group, consisting of

five rabbits, received the same dose, but each rabbit
had a five-hour fever treatment each ·week throughout
the course of the experiment.

Studies of the peri-

pheral blood throur;hout the experiment Viere made at
weekly

intervals and it was found that the small daily

doses of the drug had no consistent effect upon the
blood picture.
of pneu.monia.

Of the group of four, one animal died
The same dosage of sulfanilamide com-

bined with fever did, however, result in blood changes
in 3 rabbits.

One rabbit was killed accidentally

uuring the second week but no blood changes had
developed at that time.

Of this group the one rabbit
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that was li vine~ at the close of five VJeeks had had no
blood cell changes.

The other 3 rabbits died 10, 15,

and 24 days L<fter the beginning of the experiment.
Two of these rabbi ts had a leucopenia at the tilne of
death with decrease in all the cellular elements.

The

other rabbit also had a leucopenia but the great
reduction in the total count was due to the fact that
only 2% of the cells were granulocytes.

Unfortunately

our bone marrow preparations were unsatisfactory.
Duri~g

1939, several interesting reports

concerning the effects of drugs of the paro.-anino-benzene
sulfonamide group were nade.

Rosenthal (86) and

Nelson (73) studied the effects and histopathological
changes in hens and rabbits following administration
of sulfanilamide and sul:ranylil sulfanilaaide to
rabbits and chickens.

They found that these drugs both

have cumulative toxic effects for both rabbits and hens.
Bone 1,mrrow from 11 rabbi ts t1-,at had received repeated
doses of sulfanilamide were examined.
.studied, 3 were ncrriaJ_,
moderately hyperplastic.

~

Of 11 preparations

s..LigJ:'.'"Gly hypoplastic 'lnd 5 were
In 3

o~

.tne

~yperplastic

bone

marrov1s the proportion of early forms ot cej_ls to lute
foriw vms norr,1al.

vne .tiyperplastic tissue was i·ounct

'GO

contain increased mnnbers 01' stem cells and early granulocytic :t'orn1s and the fifth of this group of hyperplastic
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marrov:s showed that an increase in the nature for1:1s
of

cranu..Loc~;0es

na6. occurred.

It '.vas i'ounc. tb;.t one

of the typoplastic tissues had a reduction in Ghe

The bo:rn ::ia.rrm: o:t' rabbi ts

:1W:1ber of nor:rnoblasts.
~ith

tre&ted

aisulfanilamide had less pronounced changes

occur after the
c.ose s.

~rug

had been adn1nisterec in repeated

Of 9 bone ras.rrows studied, 6 'JJere normal.

Of

the three vvhich ·were abnormal, one liad. a hypopJ.asia 01·
granulocytes, one a hypopl&sia ol' normoblasts, and
one bone

2~·,arrov1

granulocytes.

prep:c:ration hacJ. a hyperplasia oi'
All the bone

stuciie s

;;1arTm·1

~;::-.~Ge

ir.1L~ature

on · Gllu

hen bone narrow given ei the1 su..Lranilaraide or di su.L1'a1

nilamide in repeated doses showed hynoplasia.
Later ir: 1939 Rosenthal and 3auer ( 87) were
able to G.enonst:.:·::•:G.:: r·.yc.roxylamine deri v2,ti ves in the
urine 01' Tatb, raobi ts, dogs, and
sulfanilar:1icle
lc.r(~:er

'.-~drn.iniste1~ed

to

afte1· they llaa l1ad

;~an

the~:1.

This

CJ.u2ntj_ties in the u.rine of' r:1an ,_;rw

in -cne utlwr aninm.Ls.

These oxicl.a ti on

'i!E1S

founG. in

:rab~:.;i t

th::en

·Jro0.ucts '.vere

1·ounu to be of greater toxicity than the orif;illa.L c.I'ug

adninistrated.
Eolitor anG Hobin::::on ( 7;:;) in 19o'd rmblished
the results o:':' tl:cir s-cuay u1
chronic toxicity us -.iell

;;~s
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cute, cur:mlative and

phar::,"acolot_:ical effects of

sul:t'anilar!1ide C:Lnr.:'.. benzyl ;::;ul:f
~oe~s

to

111~"ich

had no blood picture

sulfanilamide.

upon l<J80 ani1a1-s.

ave sul1'uni1-a:no_e for 3 week neriods

tLey

th2.t s ul:f'anilm::ide

anilmnic~e

In every case

chn~eas.

the~

observed

ver·y rmch rn.ore toxic tho.n benzyl

\"J2.S

They had no deaths of animals fed as

nuch as 45 ,zraus per kiloe;rau for 10 c:ays.
chs.nc;es they found in the

tissue~~

}!:_, tholosical

o:i' anirials ·.vhich are

3ii?1lif icunt i.vere Lirge, hyperemic, pigrn.ented S})leens.

The pier:1ent YJas both ii on Clnd non-iron conto.ir'..ing
1

The bone na:r·ro·,·,;

substances.

noder:.1tely hyperplastic.

Yi'..S

l)igrr1ent was also present in the lymph glands and in the

convoluted tubules of

t~e

kidneys.

cated that a testruction of blood

.·1hich

1

w·~~s

These findings indiele~ents

occurred

:responsible for inc1·cased stin:ulc:.tion of

bone rnarrov1.
That

sulf~'pyricii:ne

is

L':cr~.1 less

tor nice - ,'~:.s concluded by Johannsen

( ,±:7)

_nli. non-toxic

uurinc >is

investiz. tion of the toxic 2nl therapeutic effects of
the druc.

This is not the sar:e couclusion ':ihich

I'.oli tor and Robin~ on as ·well as Antopol 'J.nd Hob ins on ( :3)
reached during their experinents '.Vi th sulfap:,Tidine •,Ji th

various kinds of labor2tory animals.

Bone marrm1 hyper-

plasia of the rn.yeloc;enous ele:::ients as ·well as lyrn.pl10id

hy1Jer:)lasia and nigmentation of the S}Jleen w0.s
Peripheral blood studies 0ere not nade in these
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found.

experiments.
Very interestinc is the
Eiggins c_:ulC1 IIachelle.. ( 37)

~ork

reported by

r:L'hey i11duced anemia in rats

in a period of 10 days to two weeks by using doses of
1 grarn. of sulfanilamide to 1 kilogran of' vJeicht.

They

attributed the anemia due to a direct effect the sulfanila:-,1ide has upon the blood cells

o1'

the rat.

They

found coproporphyrin in the urine of rats and say that
its presence i:1clicates a bone

~:-iilrrov1

derangenent.

'v'fhen

they gave rats the same dose of sulfanilar:lide in connection v1ith five 50 mg. doses of nicotinic acid, anemia
developed as it had when the drug was afuninistered
without the nicotinic acid.
made.

Bone narrow studies were

No impaired hemopoiesis was founcl.

There was

some erythroid shift but the essential structure of
the bone marrow was not ir::paired.
1-Iachella and Higgins (65) have been able to
induce anemia in rats by afu1inistering doses of varying
quantity to different groups.

Their work is especially

interesting since very similar cases have jeen reported
as a result of the therapeutic use of the drug in treating infections in man.

The· experiment and its results

are described briefly.

They used four different doses

qf

sulfanilanlide on each of four
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differe~1t

groups of

rabbits.

?or

co~venience,

1

list of the doshge

~nd

groups is included.
1:0. of Hats in Grou2

Dosage

1

0.25 gms. per Kg.

6 rats

0.5

gms. per

1Cg~.

6 rats

1.0

gms. per iCg.

12 rats

2.0

gms. per IC@;.

12 rats

They were able to induce anemia in these rats in v1hich
the degree and rapidity of onset were dependent upon the
size of the dose given.

~

list of the results they

obtained is included.
1. Increased color index.
2.

Anisocytosis and macrocytosis.

3. Rapid c.:.ecrease in red blood cell count and hemoglobin.

Degree and rapidity of drop dependent on the

size of the dose.
4. Rats were thirsty, cyanotic, drowsy and
irritable during the onset and throughout the
course of the

(~_rug

adriinisti'ation after chane:es

had begun.
5. Initial drop in white blood cells was
followed by leukocytosis.
6. Steady and progressive drop in the total
hemoglobin also was observed.
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7. In the bone marrow, the erythroid and myeloid cells were increased.

A transient increase

in eosinophilic r1etarnyelocytes vms also noted.
8.

Examination of tissues was made •

Findings

were hemorrhagic gastritis, black spleens enlarged
lymph elands, and dark livers.

These animals had

a gradual recovery fro1n the anemia after the

c~rug

was discontinued.
In summarizing the vvork of the effects of
various sulfonamide drugs upon the blood cells and
henopoietic systems it is concluded that these drugs
do affect the blood cells and the hemapoietic tissues.
The presence of increr.tsed amounts of pi 0 11ent in the
spleen and in soLe cases in other tissues of the body
indicates thCct an

incre,c~sed

amount of red blood cell

destruction occurs when these Ci.rues are adninistered.
That the red cell count and hemoglobin does actually
decrease was indicated by
work.

t~ohella's

and Higrins' (37)(65)

There is little work showing changes in the

peripheral white blood cell counts since most of the
work of investigation of the harmful effects of these
drugs on experimental animals did not include blood
counts.

Since the bone -,--[arrow did have an altered pic-

ture in most instances, it is rec:tsonable to conclude
that had the peripheral blood picture been studied, the

- 1 5 -

changes found during histopathological studies of the
bone marrow would have been reflected by the peripheral
blood.
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AGRAlWLOCYTOSIS AND H.~rrnLYTIC ANEl<IA:
SENSITIVITY REliCTIONS OF TB:;_q; BOlTE: Y.~ARROVI.

Introduction
Since 193? the number of reported cases of
hemolytic anemia and agranulocytosis associated with
or following therapy with sulfanilamide and allied
compounds has inc:ceased.

That this should occur is

natural since the total number of patients t:;:eated constantly increases and provides opportunity for more
blood disturbances to develop.

Undoubtedly the few

observations of blood changes associated with these
drugs in animal vvork is due to the fact that the course
of the

e:~fect

of the drug has not been so closely

vmtched as in human beings treated with the substances,
nor have as many aninals been exposed to the drugs as
human beings.
Hemolytic Anemia
Before cons iderj.ng the red blood qell and
white blood cell disturbances fo:;_lowing the use of the
sulfonamide drugs, a brief review of the nature or
character of the conditions known as hemolytic anemia
and agranulocytosis is given.
Hemolytic anemia is a condition characterized by
hyperbilirubinemia, urobilinuria, hemosiderosis,

- l? -

reticulocytosis anQ normoblastic hyperplasia of the bone
marrow, and a high grade of leu.kocytosis if large
numbers of red blood cells are suddenly destroyed.
It may be due to peripheral hemolysis caused
by a direct hemolytic effect of certain chemicals,
bacterial toxins, and drugs or due to an idiosyncratic
effect caused by complex antigen-antebody reactions of
foreign proteins or various chenical compounds.(2?)
Examples of direct hemolytic poisons are phenylhydrazine
trinitrotoluene, hydrogen arsenide, n-propyl disulfide,
snake venoms, saponins, and bacterial toxins.

Fitzhugh

(27) says that the hemolytic effect of dinitrophenol,
acetanelid,

:~nd

antipyrine is due to an individual

idiosyncrasy of an occasional person, for these

sub-

stances do not cause a hemolytic anemia in the larger
percentage of people to whom the drug has been given.
Since the advent of sulfanilamide, both Long (60)(61)
(62)(63) and Fitzhugh (2?) think that the hemolytic
anemia which develops during sulfanilaraide therapy is
a manifestation of an anaphylactic or idiosyncratic
effect which the drug has on an occasional patient.
It is ad..111itted that hemolytic anemia is due
to complex sensitivity reactions but the factors which
are concerned in the actual production of an occasional
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sensitivity are not known.

This is true not only for

this type of allerf'Y but for all allergic phenomena.
Factors to be considered are heredity, hormonal mechanisms, dysfunction of liver and spleen, fatigue

states,

traum1tic shock, toxemias which include putrefactive
distul.'bances and various bacterial and protozoan infections, deficiency states. Radiation effects, also
are to be considered.

Fitzhugh (27), Jackson and

Parker ( 43) , I\:racke and Parker ( 55), l·ladison and
Squier (66), Pepper (76), and Rosenthal (84) all feel
that these factors are to be considered as etiological
agents in the production of various sensitivity reactions
of the blood and bone marrow •
.Agranulocytosis
Introduction.

In 1922 Schultz (90) reported

a condition which he named agranulocytosis.

The disease

he described was characterized by an acutG onset, Vlith
chills, fever, jaundice, ulcerative and gangrenous
lesions in the mouth, and leucopenia with granulocytopenia.
All of the six cases 'Which he reported occurr2d in
middle-aged women vlho had been in good heal th.
six cases were all fatal.

The

According to most workers who

have investigated and observed agranulocytosis since
that time, this is
(23) (45) (55) (66)

reg~rded

as a new disease. (27)(22)

Pepper(76), however, thinlcs that the
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condi tioc:., :i:'on1.erly known u:,; putrid so:'e throat, was
an analagous concl.i tion.

The other workel'S feel that

since blooC counts have teen done for over 50 years,
certainly the disease would have been reported before
1922 had it actually existed.

Definition.

Before the discussion of

agranulocytosis or agranulocytic ane,ina is continued,
the condition should be defined.

At first in glancing

through the literature one is confused by the large
number of different terms used to nane the syrn_ptom
co11plex.

The expressions acute granulocytic angina,

agranulocytosis, malignant granulopenia, and acute
primary granulocytopenia are synonomous terms according to Jackson and Tighe.(44)

Kracke (53) says that

the term agranulocytosis, strictly speaking, is a
misnomer for it means an increased number of
granular cells.

i~'Jl::ature

Fitzhugh (27) suggests the term per-

nicious granulocytopenia. · JTor the purpose of avoiding
confusion in this discussion, the term agranulocytosis
is being used, and the condition is defined as an acute
disease characterized b:, extreme leukopenia and granulopenia and systemic reactions which in turn may be
followed

eit~er

by no infection, localized infection,

or Generalized infection.
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~tiology.

The exact etiology is unknown.

There are, however, predisposinc etiological factors.
Pepper (76) has observed

th~t

there is a hicher incidence

of this disease among allergic patients than in nonallergic people.

}(racke ( 54) is well known for his

work both in the clinical investigation of the disease
as v1ell as the

production of the concl.ition

ex~)erinental

by various substances such as benzene, hydroquinone,
and ortho-oxybenzoic acid.

Ee says it is a disease of

the rn.yeloblastic tissues followed b':r a loss of resistance, resulting in overwhelminp; infection, but the
exact etiological agent is not known.

L.adison and

Squier (66) were able to cause a fatal agranulocytosis

in 1 of a group of 11 rabbits, by benzene drugs and feel
that these d.rur::s are in some rmnne1, responsible for a
sensitization of the bone marrow v1hich results in
sudden leucocyte decrease.

That drugs are responsible

for the condition, especially those of the benzamine
group, is the ri1ost tempting of theories, but at tim.es
cases

of agranulocytosis develop when there is no

history of the use of drugs of this group.

Kracke (55)

quotes the work of Plum who made a very extensive
survey of the incictence of agranulocytosis in Denrnark.
He was able to correlote the incidence of
with the incidence of use of

- 2l

.

ai>ninop~.'rine.

~granulocytosis

The greatest

incidence of the dise8Se occurred durine 1933 and 1934
when the largest a111ount of the (:_rug vms being- co;·:_sumed
in Demnark.

This was Vl8ll denonstrated by a e;raph he

constructed in i:1hich it '.':as de1::onstrat0d that the curve
representing the use of anino:pyrine and that representing
the incidence of agranulocytosis were parallel.
Another interesting fact regarding the incidence and distribution of agranulocytosis is that 90%
of the cases occur in the United States and G-ernany.
( 44) ( 53) ( 55) ( '76)

This corresponds to the area in

which aminopyrine was most freq_uently used a fevJ years
ago.

By the tir1e sulfanilamide became a po:pulor thera-

peutic drug, the incidence of agranulocytosis had
decreased greatly associated 'Jith the lessened use of
aminopyrine.

It is as yet too early to measure the

effects that the introduction of this new product will
have upon the total incidence but, judging by the
increasing number of reports of agranulocytosis
associated vJi th therapy with this group of drugs, it is
very likely that the incidence has made a very definite
increase.
The horrn.onal factor as an etiological factor
in the production of agranulocytosis is suspected to
play a role

because the condition occurs most often

between the ages of 30 and 40.
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The ratio of the

incidence occm'ri:1.g in wouen and men is 3 to 1, the
greatest percentage being found in women.
That the standard

of living has an effect

is well borne out by the fe,ct that before sulfanilam.ide
was introduced, the occurrence of agranulocytosis was
most corm1on in that class of people of higher econoI.'1ic
standards.(55)

Of this group nurses, physicians, and

me:nbers of the family of physicians were :rounci to have
the dise&se most freq_uently.
-v'lhen Schultz (90) described agranulocytosis
he said that the cause vms due to an acquired sensitivity
of the leukocytes, endothelium, and leukopoietic tissues
to certain drugs or other allergens.

Despite much obser-

vation and investigation since that tiiie, little more
can be said in regard to the disease today.

If it is

a bone marrow idiosyncrasr does it result in a lack of
a rimturation factor or a lacl;: of a chemotactic factor
which interferes with the delivery of the blood cells
into the vascular system?

F'itzhugh (27) calls the con-

dition pernicious granulocytopenia for he believes
that the condition is caused by an arrest in the
riaturation of e·ranulocytes ·which is analagous to the
arrest of maturation of erythrocytes in pernicious
anemia.

He believes this to be true because he has been

unable to find a decrease in the myeloid cells of' the
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bone marruw, but !:us found a hT_t!erIJlasia of the early
for~s

of granulocytes.

Furtherruore, the lesion of the

leukopoietic tissues is reversible to a certain point
if it Las not cc,,ntinued so long that apla.sia finally
results.

Reraissions of the disease are ch2racterized

by an outpouring of young cells before the nature forr11s
appear.

Fitzhugh has said thbt possibly the sudden on-

set is due to the fact that the inciting factor may
cause the cells to stick to the endothelial lining and
·thereby cause a sudden marked drop in the cell count.
That no evid.ence of abnormal distribution of granulocytes
is found during histopathological studies is explained
by the fact that the adherent cells disintegrate

r·apidly.
Overwhelming septic conditions do occasionally.
result in a profound' as well as fatal leukopenia associated with a profound reduction of the granulocytic
cells.

It is the opinion of Kracke (53)(54), Pepper (76)

Jackson (43) (44),

~ 1Iadison

and Squier (66), and Fitz-

hugh (27) that the sepsis which is often associated with
agranulocytosis is not the actual cause but rather the
result of agranulocytosis which depletes the resistence
of the tissues to infection by the lack of defensive
agents.

Domagk (21), however, does not believe that

true agranulocytosis develops as a result of the
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adrdnistration of the amino-benzene sulfonamide compounds but thut the granulocytopenia is the result of
the effect of the

etiolo~ical

agent producing the disease

for which the cirug is being used.

That a granulocytopenia

can develop in response to a severe infection is true.
Schilling (89) says that this is either brought about
by the overwhelming irritation of a severe acute sepsis
or persistent drain of a long continued inf'ection.

In

the case of sulfanilamide, however, it is hardly
possible to believe that the infections have been so
much more severe during the past few years that the
infection i tsel1' and not the sulfonamide drugs have
been responsible for the inc eased number of reports
of agranulocytosis.

In this connection the case

reported by Ives (42) is very interesting.

A negro

patient after nine days of illness with hemolytic
streptococcic angina had a total white blood cell count
of 9000 vJi th a coraplete absence of granulocytes.

The

patient had a gr<-'<yish black necrotic uer:tbrane over his
pharynx, he vvas confused, drowsy, and cor;.;.plained of a
headache and joint pain.

The lowest vvhite count was

1200, with no granulocytes one day after hospital

admission.

5 cc. of prontosil every four hours and

60 grains of sulfanilamide as well as intramuscular
liver extract

an~

intravenous pentnucleotide were
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administered as soon as the blood findings -were made.
Recovery began on the second day

'~.fter

beginning of

therapy and the patient had an uneventful course of
illness in the hospital.

In this case the sepsis was

overwhelming enough to cause a severe granulocytopenia,
and the drug was indicated because the toxic, septic
process had to be controlled.
Pathology.

The pathological changes of

agranulocytosis are located chiefly in the bone narrow.
If angina occurs, necrosis and ulceration without
evidence of 8ranulocytic invasicn occur in the mucous
menbranes, chiefly those of the tongue, nasopharynx,
and 9harynx.

Necrotic lesions are occasionally found

in the vagina, gastro-intestinal tract, and bladder.
The bone marrow changes are the most
ir:iportant pathological findirn s of this disease.
Kracke ( 53), Jackson ( 44) ( 43), Fitzhugh and Krur1bhaar

(28), and Darling, et al., (22) find that there is a
rn.uturation arrest Vii th nyperplasia at the sten cell
stage of the myeloid elements of the bone marrow if
the disease is rapidly fatal.

If the disease is pro-

longed there is an inc1:'eased number of plasna cells and
lyrnphocytes with hypo1)lasia of the myeloid cells.
There is, however, no evidence of degenerative changes
occurring in the bone n"arrow cells.
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If the bone marrow

is degenerated it is either the result of an infection
or poor fixation of the tiDsue.

Bone marrow 1'rom

patients who are recoverinB froG the infection has
increased nur,1bers of raore nature cells.

Rosenthal (:35)

finch; tli::;t tha bone ma=-rovJ is aplastic.

Pepper ( 76)

also believes that an aplastic as ··,ell as a degener2ted
bone w-1.rrm. if; found in these conditions.
1

It is possible,

as Jackson (44) says, to misinterpret bone marrow findings, especially if the tissues have been i:nproperly
fixed.

It is also possible

th~t

Pepper (76) and Rosen-

thal (85) both examLled bone marrov1 frm1 patients '1vith
a prolonged course of the disease.

Jackson (44) also

thinl;:s that the original report of the bone L1arrov1 findings by Schultz ( 90) ar·e also frequently wisinterpreted
to rr1ean aplasia of the bone rnarro·i.1 instead of a maturation arrest.

To us it seems that the conclusion may be

reached after having examined the reports oi' the vc:irious
authorities that the bone marrow may be either aplastic,
hyperplastic, or hypoplastic.
Course of Disease.

Clinically, the course of

the disease has an acute onset.

Often there is a prodomal

period of malaise. The fever is high, ranging from 104°
to 1070 F.

The patient is prostrateo., usually

con~lains

of severe headache, has chills and a sore throat.
Often there are ulcerative lesions both in the nose, mouth
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and throat which have a peculiar gray green appearance
with ve:_'y little or no inflammatory change.
is foul.

The breath

.1:;.long v1i th these finc:iings ancl symptoms there

is extreme leuko:penia v.Jith a great reduction in granulocytes.

Often no granulocytes are found in the

peripheral blood ancl the total count may be as low as
only a few hundred cells.

A few reports told of

counts less than 100 white blood cells per cubic 1nillimeter.

Often positive cultures are obtained from the

blood, but the bacteria are not recarded as the
etiological agents of agranulocytosis, but the result
of invasion of the body tissue2 as a result of the
absence of the defense barrier

~hich

the cranulocytes

provide in protecting the body against bacterial infect ion.

The disease has a rapid course and may terminate

fatally in frori 2 to 6 days or recovery when it occurs
is complete in 2 weeks.
mortality.

Jackson ( 44) reports a 78fo

Kracke (53) found that

affliced with agranulocytosis died.

85~;

of 250 patients

Liadi;rnn and

Squier (66) observed 14 cases following aminopyrine
injection.

Of this group 8 died.

It is uncertain what

the exact mortality rate is, but there is no doubt that
it is high.
Diagnosis.
followine; findL1gs:

Diagnosis is based upon the
Hemorrhage doec' not occur, few

-
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irm_ature white blood cells are present in the blood at
the heicht of the disease, neither the livernor the
srJleen are enlarged, and l·yrr1phadenopathy does not occur
except that ex})lained by local areas of sepsis.

In

addition to these findines recovery, if it occurs, is
CO!tplete in two ·weeks, relapses are uncorDraon.

Usually

careful questioning and investieation ·will elicit the
fact that soEe form of a benzene or aminobenzene drug
has been used.

Bc:,ne marrow chant::es may be an aid to

diagnosis, but if we go on the assumption that it may
be aplastic, hyperplastic or hypoplastic, it is necessary
to correlate all the finGings to arrive at a definite
diag·nosis.
Differential diacno:ds may be very difficult.
( 44) ( 45)

Ott.er conditions from which it IilUSt be

differentiated ar0 overv1helmin2; infections; benz ol,
gold, bismuth and arsenic poisoning; acute leuh:emia;
aplastic anemia; and acute infections such as typhus,
raeasles, r:mmps, influenza, malaria, dencue fever and
roseola which characteristically
counts.

~lave

lovJ total v1hi te

Careful blood studies, thoroue;h

exar~ination,

and caw:ete histories are all valuable aids in establishinc a diagnosis.

An aplastic bone r:iarrov1 with blood

findings inci.icatillC a severe anenia, thror:lbopenia, and
neutronenia is typical of aplastic
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ane~ia.

If thare is

a hi;; tcry oi.' ucir1ini ~ 0.tra ti 011 of col cl, ::.rsenic, bisr:mth,
or tenzol before the

o~set

of such f

indin~s

the

etiolozy of tha aplastic anenia is ostablished.
Acute infections ( 53) seldon cause
diagnostic difficulty

becau~1e

i~~uch

of cheracteristic sic:;ns

and sy1npto.i,1s which do not harmonize '.Ji th the blood
~yscrasias.

Both acute leukemia as well as a neutro-

penia due to an overv1hGlr:dnr sa1;s is may be very cliff icult to dif:_'erentiate froe
neutropenia

B.{~;ranulocytosis.

associate~ ~ith

seps is by Kracke. ( 5~))

The

sepsis is termed acranulo-

This condition rnay follov1 surrdcal

procedures (81)(102) aB well as acut3 infections (42) (9)
and it I:1ay be very difficult to cleternine '::hether the
s:rr1:9tons and firnli1ic:s are pathognononic of an

idio~Jathic

agrarrulocytosis or of an exhaustion or intoxication caused

o:/

the s e·otic process.

A bone

:1aITO'..'

strnly may give the

only clue by degenerative and toxic chances found
the cells.

~ithin

Severe septic processes of this type are apt

to have an associ.=i.ted seco:J.dary a;:ienia \'Jl1ich may also be
helpful in er:Jtablishing the truo dia[·T1osis.
Jackson (45) warns of the ease in which acute
leukemia and agranulocytosis

1~iay

be

cor~fused.

Only

careful study of the patient's hematological picture
correlated '.:i th the physical findings will, in so:ie cases
result in a definite diagnosis of either one of these
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EE:.:OLYTIC J\IC1 :IA ASSOCIA'l1:S:D ·. IITE SULFONILAI.IIDE

Al'TD RELATED COI:FOUIWS
Introduction
Both mild, slowly progressive he:nolytic anemia
and acute

heraolytic anemia vvith a sudden clrop in hemo-

globin and r·_ d cells aI·e afrnociat·ed ':tith the acLministration of sulfanilamide and sulfapyridine.
Progressive Hemolytic Anemia
Lone (63)(59)(61) and

~ood

(106) as well as

Garvin (30) have all observed that a progressive hemolytic anemia with a fall of from
occurs in sone p:::tients.

10~&

to 20% hemoglobin

Jennings s.nd Southwell-Sanders

(46) made the first report of a slowly progressing
hemolytic anemia associated with sulfanilamide ad.ministration.
who

This is most often noticed in those patients

have received the drug for several weeks and most

often appears after the tenth day.

The reticulocyte

count increases and there may or may not be a slight
urobilinuria.

All of these three workers make their

statements after having observed many patients, but they
do not state the percentage of patients treated over a
long period of tirne that developed the low grade,
chronic hemolytic anemia
Incidence.

Bigler, Clifton, and
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~:rerner

(7)

studied the bloocl picture of 33 patients v1hile recei ving sulfanilarnide.

They observed no severe 2nenia, nor

did they find that any of their patients developed a
low grade aner1ia.

In fact, they say that often the

hemoglobin of their patients apparently increased.

Counts

were done two times each week during a period of 28
days on 50 ambulatory patients beinB treated by sulfanilarnide by Britton and Cowkins.(10)

The dosage

prescribed was 0.5 gram three tines a day for 14 days.
During that time they detected no evidence of a hemoglobin or red cell decrease.

Hageman (32)(34)

in

reviewing 114 cases treated with sulfanilamide found one
case of hemolytic anemia.

Carn.pbell ( 12) observed the

blood picture of 10 cases being treated with sulfanilamide.

Anemia was not found but the reticulocyte

count increased.

It is possible that destruction of the

red blood cells did occur, but it was so slight that
anemia was not detectable because the bone marrow was
able

to replace red cells as fast as they were destroyed.
Long, Bliss, and Feinstone (63) have observed

that chronic anemia may also result when sulfapyridine
is used.

Hodes, et al., (39) studied 71 cases of

pneumococcic pneumonia treated with sulfapyridine and
found no significant hemoglobin change.

Barnett, et al.,

(5) report no anemia from sulfapyridine therapy in a
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group of 23 cases.

No anemia is reported by Evans,

et al., (25) who used sulfapyridine to treat pnemnonia.
Rosenthal and Vogel (84) who use the sane d.rug have
found that henolytic anemia does occur.
Discussion.

This type of anemia is not

regarded as a grave conplication of sulfanilamide
therapy.

Long and Bliss (59)(61)(62)(63) do not regard

this complication of severe enough consequence to discontinue the ..~rug unless the hemoglobin has dropped below
60?~.

The bloou regenerates quickly if the drug is

stopped and if the infection is not yet controlled and
the hemoglobin has dropped to the
continuation of the

c~rug

60~b

level they advise

v1i th a blood transfusion.

Acute Hemolytic Anemia
The acute hemolytic anemia which develops is
both spectacular and serious.

Harvey and Janeway (38)

made the first report of this toxic effect of sulfanilamide.

The early

s~.~mptoms,

before the anemia

develops, are nausea; dizziness; increased urobilin;
fever; and symptoms of

tox~city.(106)(30)(61)

Other

findings reported by these workers, as well as those
whose cases are tabulated in Table I, are a rapid, and
pronounced fall in the hemoglobin antl the number of
red blood cells.

The count may drop as much as
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TABLE

I

Tabulation of Cases of Hemol
Drugs of the Para-Amino-Benze

Total
Drug

Sex

Reference

Age

Antopal
Applebaum
Goldman

Male

8 gma.

34

Prontosil

Antopal
Applebaum
Goldman

Male

90

5

64

Rosenthal
Vogel

Male

Wood

Sulfan.

9

3

Pneun

36

Hours

9

Lil!-· 66

28

Mastc
Masto:l

3
StrE

gms.

Sulfan.

*

4

Tonsi

gms.

Sulfapy.

Male
-:t-

Diagn

24 gms.

Female
Kaletsky

gms.

Sulfan.

Total
Days

6

Pneur

Bone marrow was very hyperplastic w:
proliferation.

TABLE I

(Con

Tabulation of Cases of Hemol:
Drugs of the Para-Amino-Benze1

Reference

Sex
Age

Total
Drug

Total
Days

Diagn<

Wood(l06)

Male
36

21 gms.
Sulfan.

5

Tonsi:

7.8 gms.
Sulfan.

3

Tonsi

2 gms.
Sulfan.

2

Same Pt.
1 Yr. later
Rosenblum
Rosenblum

Male

Nelson
ScottYoung

Female
32

Harvey
Janeway

Male
36

48

gms.
Sulfan.

22.8 gms.
Sulfan.

Tonsi

23
Days

5

Ot. M,

Goner
Strep
Sore 'Il

TABLE I

(Con 1 t)

Tabulation of Cases of Hemolytic Anemia Due to
Drugs of the Para-Amino-Benzene-Sulfonamide Group

Reference

Sex
Age

Total
Drug

Total
Days

Diagnosis

Lowest Hb.
R.B.C.

Treatment

Outcome

2

Peritonsillar
Abscess

18%
2,000,000
Dev. in 36 hrs

2 Blood
Transfs.

Recovered

Dev. in 7 deys

2 Blood
Transfs.

Recovered

Harvey
Janeway

Female
26

Harvey
Janeway

Female
10 mos.

8.92 gms.
Sulfa.n.

7

Mening.
Meningitis

Kohn

Female
1 Yr.

6 gms.
Sulfan.

6

Ct.Media

6.o gms.
2,000,000

Intramusc.
Blood

Recovered

8

Mening.
Meningitis

50%
2,500,000

Iron
Transf.

Recovered

Jennings
SouthwellSander

Male
45

12.2 gms.
Sulfa.n.

30gms.sulfan.
6gms.pront.
flav.

two million in 24 hours.

L:arked reticulocytosis, leu-

kocytosis, bilirubinemia, urobilinuria, porphyrinuria,
jaundice, and occasionally jaundice are also associated
with this condition.
In considering predisposing

f~ctors,

it was

found that no one type of infection was associated with
the acute anemia.

The size ol' the dose and the concen-

tration of the Qrug in the blood do not seem to be
factors for both high and low values were associated
with the syndrome.
in 19 of

~ood's

The carbon dioxide corribining power

(106) 21 cases of acute hemolytic anemia

cases was within normal limits.

Table II is a table

taken from a report by Wood (106) aemonstrating a
hypersensitivity of the red blood cell system to sulf'anilamide after the four patients had recovered from a
previous attack of acute hemolytic anemia.
is a case cited

b~ ~illis.(105)

Case A.D.

All of' the

patients had fever.
Incidence.

Acute hemolytic anemia is not more

prevalent in one sex than in the other.

It is, however,

more prevalent in chilclren than adults.

'Nood ( 106) has

observed 522 patients treated VJith sulfaniJ.amide.

Of

this group 144 were children and 378 were adults.

A

total of 21 cases of acute hemolytic anemia occurred in
the children's group and 9 in the adult group, or 8. 377;
and 2 .4~a respectively.

No large group of patients
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TABLE
Table from Wood (106) Summarizing Five
Anemia Took Place Followin_g_a Second c,

First
Course of Trea tme:
..
,--...... .... -..-,---~-·------

Sex
Age

Diagnosis

Days of
Treatment

Total
Dose

No.1

Male
36

Acute
Tonsj_lli tis

5

21.9

No.2

Male
4 da-ys

Ophthal.
Neo.

111.

7 .~.

Pulmon.
Tb.

7

11.1 .• 0

Patient

Male
No.3

2

No.4

Female
7 Mos.

Otitis
Media

3

4.5

No.5

Female
9 Mos.

Pyelitis

3

5.8

Dr

%

treated with sulfapyridine has as yet been reported.
Hemolytic anemia, however, also occurs in patients
treated with sulfapyridine.(29)(84)

No hemolytic

anemia associQted with either prontosil or disulfanilamide has been reported but 2 cases treated with
diamino diphenyl sulfone are reported.(62)
Course and Prognosis.

The onset of the

disease is fror. 24 to 72 hours after the beginning of
the drug administration.

The maximum anemia occurs

from the third to seventh day, most often on the fifth
day.
The m.ortality rate is low because the condition
responds well to withdrawal of the drug and blood
transfusions.

Two fatal cases are reported, one by

Wood (107) and the other by Koletsky.(52)

(See Table I.)

The case reported by Koletsky died 6 days after the beginning of the first dose of sulfanilamide and 2 days
after the drug was discontinued.
available.

No transfusions were

The death following the development of

anemia reported by Wood (107) is evidently due to the
fact that transfusions were started too late in the
course of the disease.

The drug had been discontinued

on the sixth day but no transfusion was given w1til the
twelfth day.

The patient died on the sixteenth day

after the drug had first been started.
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Possible Li.echanism.

That the acute hemolytic

anemia, v1hich develops during the course of therapy with
several drugs of the sulfonamide group, is due to an
individual idiosyncrasy is very evident.

That the con-

dition does not occur in every case is one proof of this
and the fact that 3 out of 4 patients have a recurrence
of the s:yraptoms when the drug is repeated is evidence
that these patients are hypersensitive to the drug.(63)
As with all idiosyncrasies, the mechanisli. by ·which it
works is not understood.

There is no bone marrow

depression as is indicated both ~y the reticulocytosis
and leukocytosis as well as by bone marrm·; studies that
reveal a hyperplasia of' both erythroid and nyeloid elements.

The drug does not hemlyze the red blood cells of

these patients, nor are the cells of these patients more
easily her10lyzed by hypotonic saline than in normal
patients. (53)(106)(107)

Histopathological study of

other tissues, besides the bone !arrow, reveals changes
typical of any severe hemolytic anemia.

The most typical

finding is hemosiderin deposits in the tissue.

So the

pathology gives no clue to the mechanism of the anemia
production.

Both Long (63) and Wood (106) report.the

presence of porpllyrin in the urine.

Ri.:n.ington ( 82)

has found that porphyrin increases when sulfanilamide is
eiven to patients.

he believes that the porphyrin
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production is not related to the bilirubinernia associated
with red cell destruction, but he thinks it is produced
because the sulfanilamide r.iay possibly be responsible
f'or a disturbance in pigment metabolism with a deepseated effect upon the hemapoietic system.

Ee says that

hemoglobin forns bilirubin without passing through a
porphyrin stage.

It is necessary to conclude that the

mechanism of the production of hemolytic anemia by
drugs of this group is not understood.
Treatment.
simple.

Treatnent of hemolytic anemia is

Two main conditions must be fulfilled.

In the

first place, the drut; responsible for the. idiosyncrasy
must be eliminated.

This is accomplished by forcing

fluids and discontinuing the drug.

These drugs are

excreted almost entirely by the kidney (68)(75) so
water diuresis is very necessary.

In the second place

blood transfusions are necessary not only to tide the
person over the critical period until the bone r.iarrow is
able to regenerate blood cells to replace those destroyed but also to prevent irreparable
case of profound anemia.

tissu~

damage in

I.iany of these patients becorae

so anemic that cyanosis is not present even though a
considerable portion of the remaining hemoglobin has been
changed to methemoglobin.(78)

Furthermore, it is possible

for toxic effects to manifest theEJ.selves from 3 to 4 days
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after the last dose(l8), and it seems too great a risk
to take a chance and hope that the hemoglobin and red
cel~will

not drop farther even though the drug has

been discontinued.

That these methods are satisfactory

in preventing mortality is indicated by reports.of
Long (63), '/food (106) {93) (38) ('74).

Occasionally (63)

if the infection is very severe and there is no control
of it yet established when the anemia occurs, it is
justifiable to continue the drug therapy provided the
patient is carefully watched and repeated daily transfusions are given to control the anemia.
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LEUKOP?.:NIL N,.'U AGRr.I'TITLOCYTOSIS A.GSOCI.Ar:L1ZJ ·.'ITE
SULFAlTILAl.'.IDE AI''.D H3L1~TED COEPOlJl:rns.

Introduction
The literature concerning disturbances of the
white blood cells due to the benzene-sulfonamide drugs
is very much greEJ.ter in amount than that relating of
red blood cell disorders.

Undoubtedly this is due to

the fact that agranulocytosis is a very severe and often
fatal complication following not only the para-aminobenzene sulfonamide group but also the benzene drugs,
es1-:iecially the benzamines, to which the group under
discussion belongs.(56)
Agranulocytosis is, however, not the only
disturbance of white blood cells encountered when the
effects of these drugs on the leukocytes are reviewed
Other conditions are leukopenia and hyperleukocytosis.
Leukopenia
Trunper in 1937 (77) in a letter addressed to
the lfow England Journal of l'Iedicine saicc that two
cases which he had been treating

~ith

prontosil and

prontolyn had had nmrked reductions in the total white
count.

One patient with a septic mastoid had dropped

from 18, 800 white blood cells to 4, 000 with 357~ granulocytes.

The white count in the other patient suffering
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from puerperal sensis dropped from 20,000 white blood
cells to 5,000 with 50%-60% granulocytes.

This seems

to be the first report which appeared in the literature
vvhich indicated that sulf'anilamide and prontosil may
affect the blood picture in some manner.

In both

instances the white cell count rose when the drug was
discontinued.
Some believe that the derivatives of sulfanilw1ide as well as that drug itself have a depressive
ef~ect

upon the white blood cells.

This is the opinion

of Bigler (7) who studied the leukocyte response of 33
patients to sulfanilamide therapy.

Since they observed

the nu..111ber of leukocytes became less during the course
of treat:nent, they concluded that the cell drop was an
effect upon the cells and not a natural result of the
termination or recovery from the original infection.
That tlJ_ey made that conclusion seems especially strant;e
when it is fOWld during examination of their reports that
no one type of cell v1as decreased out of proportion to
the other cells.

Although they did find that in three

instances the total count was slightly below 5000, no
evidence of granulocytopenia is present.
Britton (10) observed a group of 50 ambulatory
patients who received the drug for two weeks, but whose
blood counts v;ere done 2 times a week, both during the
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treatment and the followine two weeks.

Of this group

32 had no marked variations in white cell counts.
14 cases the count dropped to

bet~een

In

5000 and 4000

and 4 cases had white cell counts th8t dropped below
3000.

At the beginning none of the patients had either

a leukocytosis or leukopenia.

Blood counts were done

on 17 untreated normal controls during the same period.
The types of cases being treated consisted of cervical
eriosions, urinary infections, gonorrhea, and one c&se
of syphilis.

Of their 14 cases whose count fell to be-

tween 5000 and 4000, 2 cases were lowest during the
first week, 3 cases lowest during the second week, and
9 cases were lowest during the third week, that is,
the first week after the medication had been discontinued.
Those 4 cases in ·which the white cell counts dropped
below 4000, had that occur during the third week.

In

only five of their cases was a true neutropenia
observed "nhere the granulocyte count dropped below 2000.
After analyzing their findings, they found tlIBt there
vms a tendency for the average total white cell count
to drop during the first wetk and remain low for the
following two weeks with a rise to norEal occurring at
the end of the third week.
TiNo hundred and. fifty cases treated with

sulfapyridine were summarized by Lloyd, et al. (58).
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They say that a small proportion of these patients had
slight but definite decrease of the leukocyte count
associr1ted with a neutropenia nnci relative lyrnphocytosis.
They observed no dangerous depression of the rranulocytes
and say that the v1hite count quickly rose to normal levels
vd th discontinuation of the

c~rug.

Hodes, et al., (39) treated 71 cases of
pneumonia with sulfapyridine.

He reports 5 cases of

mild granulocytopenia and one case of severe granulocytopenia v1hich all recovered c::_s soon as the drug was discontinued.

Flippin (29) reports one ca.:;e of leukopenia

in a group of 100 cases treated with sulfanilamide.
From the reports of the results of sulfapyridine
therapy it is apparent that a depression of leukocytes
is

a~1sociated

vvi th the administration of this drug.

That the drug is an etiological factor concerned in the
cell depression is evident since the count returns to
normal after it has been discontinued.
decreases in the total

v;t~ite

Whether these

count are in the nature of

a mild hypersensitivity reaction or due to a direct
toxic effect upon the white blood cells or marrow, we
have no way of knowing.

That either one of the two

conditions may exist is possible.

In every case the

condition was mild anc5 no other toxic symptoras were
associated with the change in the blood picture.
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In the 408 cases observed bv Long (62)(63),
no mild or transient Cdses of leukopenia associated
with •ranulocytopenia are noted.

The only white blood

cell disturbances encountered was one case of agranulocytosis which developed during treatment at the
hospital and one case of agranulocytosis which developed
in an out-patient.

Patients in their care who had

leukopenia as a result of an infection recovered f'ron
this sy.mpton as soon as the infection ·was brought under
control either by sulfanilamide, sulfapyridine, or some
related drug.

Long and Dliss, therefore, conclude that

these drugs have no ;.1irect effect upon the white blood
cells except th<-1t occasionally agranulocytosis may
occur associated with the a&ninistration of these Li.rugs.
Reference to a case cited by Ives (42) has
been made earlier in which agranulocytosis associated
vii th a heri1olytic streptococcic angina improved after
sulfanilrunide was given.

Long (63) also has said

that sulfanilamide is indicated in those cases of leu- .
kopenia and agranulocytosis associated with an infection,
for the removal of the infection will remove the
etiological f· ct or.
0

It seems, hmJever, that this

opinion should be slightly modified.

Strasser and

Singer ( 96) say that if any disease which is characte:r:ized
by leukopenia is treated by sulfanilamide or its
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derivatives the depression of the white blood cells is
apt to inJrease to an even still greater degree.
He cites a case of miliary tuberculosis treated with
prontosil in which agranulocytosis developed.

This was

t eated with nucleotide and the white count rose.
argues for the curnulative effect of the drug.
3 day course of treatment vJi th the same drug

This

Later a
re~rnl ted

total disappearance of granulocytes from the blood.

in
The

count rose after' the drug had been discontinued and a
transfusion had been given.
Agranulocytosis
The first cases of agranulocytosis associated
·with sulfanilamide and prontosil afu:iinistration were
reported by Pluc'-er (101); _Borst (8,); and Young (108) in
1937.

Each of these cases terminated fatally.

After

these accidents had occurred, more rsports were made of
both severe granulocytopenia and agranulocytosis resulting when this group of drugs were given.
Etiology.

Long (62) thinks that the agranulo-

cytosis which occurs and is associated with therapy by
sulfanilai11ide or other members of the group is different
from the type of reaction seen in the cases of agranulocytosis

or profound granulocytopenia associated with

aminopyrine.

He bases this opinion on the fact that often
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patients who have recoverec_

fro~:

the

dise~~se

do not

subsequently develop granulocytopenia or other synptoms
when test doses are given, or therapy is reinstituted
for other inf'ections.

Schwentker (92) also has observed

a lack of hypersensitivity to these drugs when they are
adninistrated.
Jennings and Southwell (84) believe the condition of ai:::;ranulocytosis follov1ing sulfanilamide administration is similar to the cor::.di tion ·which occasionally
occurs

follov1inr:~

the administration of benz ol, tolu ol,

anO. their rutro and. anide product2.

'rhey reminL. us of

the fact that sulfanilanide and its rel:,_ted substances
are

me~1bers

of this group of drue;s.

"/i th amido-pyrine,

1

how ver, it is not known hov.7 i;iuch of the
cause an attack.

c~ruc

is a:pt to

'Ji th sulfanilamic1e, hoi:1ever, it has

often been observed

thc~t

ufter 20 gra1:.1s t'.ave been admin-

istered in a period usually over 14 days the bloo J
1

disturbances of the

~hite

fact th3.t da!!l2.f:e to the
m1til after a

le.r.~;e

cells are apt to occur.

~;hi te

The

cells does not occur

amount of the drug 11:::.s been given

for a lon{:· tLr_e causes Shecket e.nd Price (93), Taub and
Lefkowitz (99) to think that it is the cw,iulative e1'fect
of the drus given over a lori:; period of tine that fiEally
wears out the myeloid tissue of the bone marrow.
large doses do not affect all natients in the same
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Since

manner it v1oulcl

Sl3e1~1

that or:.ly th0 ore;anically G.eficient

marrows are affected.
Allen and Short ( 1) , ==cGuire and : ~cGuire ( 70) ,
and Jones and

I~ller

(49) have been ablo to renort

sens i ti vi ty to the drug by patients a:.Cter they had
recovered frod agrunulocytosis after a course of sulfanila::iide treat.!.'lent o.nd therefo:r:·e recard it as a :reaction
of the he:v1apoietic system of a hypersensitive nature.
Again we mention another

f~ctor

previously

cited (96), tll3.t one should })roceed cautiously v1ith the
use oi'

pro~1tosil

if there is already evidence of some

'Vhi te blood cell dyscrasia.

One ca::e of'

ae:~ranulocytosis

which developed in a patient that had railiary tuberculosis
was cited.

Coxon and Forbes ( 15) reported a case of

typhoid which developed an

acranuloc~tosiE

after the

patient had been treated with sulfapyridine.

Four cases

of whoopi:ig couc;h v1i th bronchopneunonia, which were
treated v;i th s ulfapyridine and also developed ac;ranulocytopenia are reported by Dolgopol.(24)

All the

diseases, tuberculosis, whooping cough and typhoid, are
characterized by neutropenia and vJe v:or::.der if the
agranulocytosis v1hich occurred nay not have been influenced by the fact the.t

chai1;·0~

s already vJere present

in the bone marrow before. the clruc therapy began.
Sex may or l"lay not be a factor in the production
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TABLE

III

Tabulation of Reported Cases of
Granulocytopenia and Agranulocytosis
Reference

Borst
Allen
Short

Diagnosis
Pye locystitis
Barthol in
Abscess

Sex
Age

Total
Drug

Female

64 gms.

61

Female

18

Alpert
Forbes

Rheumatic
Fever

Female

Barnett
et al.

Pneumoc.
Peritonitis

Female

Berg
Holtzman

Gonorrhea

11

10

Male

22

Pront.

18 gms.

Sulfan.

Total
Days

Onset of
Diagnosis

Lowest
W.B.C.

Treatment

Outcome

39

38 Days

960
1% Gran.

None

Died

19

19 Days

2400
0 Gran.

None

Recovery

3200
0 Gran.

Liver E.xt.
Transf.

Recovery

75

Liver Ext.
'I'rans.

Died. Hem.
after drain.
neck abscess

12 gms.

Sulfan.

80.9 gms.
Sulfapy.

38.0 gms.
Sulfan.

7

26

3 Days Later

0 Gran.

27

27 Days

1600
1% Gran.

Died

TABLE

III

Tabulation of Reported Cases of
GranulocrtoEenia and Agranulocrtosis
Reference

Diagnosis

Sex
Age

Total
Drug

Bresgen

Pyelitis

Female
55

33.62 gms.
Pront. &
Sulfan.

Corr
Root

1st Presc.
by Osteopa.

Female
22

35 gms.
Sulfan.

Female

42

54 gms.
Sulf apy

Female
40

21.7 gms.
Sulfan.

Coxon
Forbes

Typhoid .

Culbreath
Ellenton

Puerp.Sep.
Malaria

Cutler
Crane

Female
Salpingitis

Total
Dara

Onset of
Diagnosis

Lowest
W.B .C.

Treatment

Outcome

400
0 Gran.

Transf.
Liver Ext.
Nucleotide
X-Ray

Died

15

800
Neutro.
2% Eosin.

Transfs.
Pentnucleotide

Died

17

100
0 Gran.

Nucleinic
Acid
Calcium

700
0 Gran.

Transfa.
Pentnucleotide

Died

1050
0 Gran.

Transfs.
Pentnucleotide

Recovery

21

21 Days

8~

7

17 Days
After last dose

11~

Days

Recovery

TABLE

III

Tabulation of Reported Cases of
Granulocytopenia and Agranulocytosis
Reference

Diagnosis

Sex
Age

Dolgopol
Hobart

Pneumonia

Dolgopol
Hobart

Pertussis
Pneumonia

Female

Dolgopal
Hobart

Pertussis
Pneumonia

Female
18 mos.

Evans
Gaisford

Pneumonia

Child

Gray
Adams

Pneumococic
Meningitis

Male

Hall

Pneumonia

Female

4
1

19

Male

9

Total
Drug

49

gms.

27

gms.

Sulfa.py.

Sulfapy.
ll~.. 5 gms •
Sulfa.pyr

No Record
Sulfapy.

77 gms.
Sulfa.n.

45

gms.
Sulfan.

Total
Days

14
15

Onset of
Diagnosis

11~

Days

3 Days
.After last dose

4

4 Days

11

11 Days

17

2 Days
.After Jast dose

21

21 Days

Lowest
W.B.C.

Treatment

Outcome

2000

0 Gran.

Liver Ext.
Pentnucl.
Transfs.

Died

2500
0 Gran •

Liver Ext.
Pentnucl.

Recovery

4200

24%

Gran.

None

Recovery

1100

Recovery

O Gran.
2000

24%

Gran.

2000
0 Gran.

None

Recovery

Yellow bone
Marrow Ext.

Died

TABLE

III

Tabulation of Reported Cases of
Granulocytopenia and Agranulocytosis
Reference

Dia~osis

Sex
Age.

Hoffman

G.C.
Arthritis

Female
19

Trumper

Septic
Mastoid

Hohmann

Gonorrhea

Ives

Septic sore
throat with
Agranulocy.

Johnston

Puerperal
Sepsis

Total
Drug
49.2 gms.
Sulfan.

Total
Da1s

18

--

--

-

Male

24 gip.s.
Streptoc.
7.2gms.Pront.

12

--

Ma.le
52

Female

23

-61.3 gms.
Pront. &
Sulfan.

20

Onset of
Diagnosis

Lowest
W.B.C.

Treatment

Outcome

3 Days

.After last dose

1350
0 Gran •

Transf.
Liver Ext.
Fe.Sulf.

Recovery

--

4000
35y& Gran.

Withdrawal
of Drug

Recovery

Drug discontinued because a drop occurred in the number
of granulocytes on the 12th day. Decrease did not continue after drug discontinued.
Agranulocy.
Before Drug
Given

20 Days

1200
0 Granu.

1520

0 Gran.

Liver Ext.
Pentnucle.
Transfs.
Pentnucle.
10 Tab.allowed

Recovery
Soon as Drug
Began

Recovery

TABLE

III

Tabulation of Reported Cases of
GranulocztoEenia and Agranulocztosis
Reference

Diat:5!!osis

Sex
Ag_e

Johnston

Puerperal
Sepsis

Female

Jones
Miller

33
Male

Gonorrhea

26

Female

'l'otal
Drug

Total
Dazs

Onset of
Diagnosis

68.45 grns.
Pront. &
Sulfa.n.
over
30 gms.

16.25 gms.

20

20 Days

2300
5% Gran.

Yellow bone
Marrow cone.

Recovery

25 Days

1000
0 Gran.

Transfs.
Pentnucle.
Bone Marrow

Recovery

Rheumatoid
Arthritis

Female

35

Sulfa.n.

30

30 Days

Rheum.Fever
Endoca.r.

Ma.le

Model

54 gms.
Sulfan.

18

18 Days

20

Transfs.
Pentnucle.

22 Days

McGuire
McGuire

27 gms.

Outcome

22

Pyelitis

Sulfan.

Treatment

3500
0 Gran.

Marcus

35

Lowest
W.B .C.

25

450
0 Gran.
300
0 Gran.

5

Tab.All~wed

X-Ray.IntraMuse.Blood.
Pentnucle.
Transfs.
Pentnucle.

Recovery

Recovery.
Sympt.Recur
with Drug

Died

TABLE III
Tabulation of Reported Cases of
GranulocxtoEenia and Agranulocitosis
Sex
Age

Total
Drug

Reference

DiaB,!!osis

Pearson

Sinusitis

Plumer

Subacute
Bacterial
Endocarditis

Female

Subacute
Bact.Endocar.

Male

Sailor

39

Sulfan.

Schwartz
Garvin
Koletsky

Chancroidal
Ulcer

Male

32

56 Gms.

Sulfan.

Schwartz
Garvin
Koletsky

Gonorrheal
Arthritis

Male

66 gms.

Female

60

54

57

36 gms.

Pront.
Album.

43.25

gms.

Sulfan.

Total
Dais

Onset of
Diagnosis

Lowest
W.B.C.

24

6 Days
After Last
Dose

600
2% Gran.

23

3 Days
After Last
Dose

400
0 Gran.

None

Recovered

23

23 Days

200
0 Gran.

None

Died

282.6 gms.

Sulfan.

21
13

Treatment
Tranfs.from
Leukemia
Patient

Outcome
Died

18 Days

300

0 Gran.

Pentnucle.
Liver Ext.
Transf.

Died

13 Days

1350
20% Gran.

Pentnucle.
Liver Ext.
Transfs.

Died

TABLE I I I
Tabulation of Reported Cases of
Granulocytopenia and Agranulocytosis
Diagnosis

Sex
Age

Schwartz
Garvin
Koletsky

Erysipelas

Fem.ale
22

Schwartz
Garvin
Koletsky

Puerperal
Endometri t:ts

Female
26

100 gms.
Sulfan.

Shecket
Price

Pneumonia

Male
45
Male

Reference

Bronchopne.u.
Strep.Sore
Shull en berger
Throat

Sutherland

Spesis

44
37

Tota.I
Drug
15 gms.
Sulfan.

Total
Days

3

Onset of
Diagnosis

3 Days

Lowest
Treatment

Outcome

2000
25% Gran.

Pentnucle.
Liver Ext.

Recovery

Recovery

W.B.C.

17

19 Days

400
0 Gran.

Pentnucle.
Liver Ext.
Trans:fs.

64 gms.
Sulfan.

15

15 Days

50
0 Gran.

Pentnucle.
Trans.fa.

Died

52.39 gms.
Sulfpy:.

21

1200
0 Gran.

Pentnucle.

Recovery

1500
0 Gran.

Liver Ext.
Pentnucle.
Transfs.

Recovery

52 gms.
Sulfapy.

12

3 Days
After la.st dose
3 Days
Arter last Cbse

TABLE III
Tabulation of Reported Cases of
Granulocytopenia and Agranulocytosis
Reference

Diagnosis

Sex
Age

Total
Drug

Fe.male

18 gms.

41

Sweeney

Sore Throat

Taub
Lefkowitz

Pneumonia

Female
66

Rosenthal
Vogel

Recurrent
Pneumonia

Male

Rosenthal
Vogel

Osteomyelitis

10

Rosenthal
Vogel

Pertusis &
Bronchopneum.

Female

Total
Days

Onset of
Diagnosis

Lowest
W.B.C.

8

Had taken
Previously ?

1800
18,& Gran.

3 Days

~

gms.
Sulfan.

4

Recovery

10% Gran.

Liver Ext.
Transfs.

Recovery

14

17 Days

300
0 Gran.

Transf.

Died

16

16 Days

1100
0 Gran.

Transf.

Died

15.25 gms.

?

During 4th
Week

95 gms.
Sulfan.
gms.
Sulfan.

Daily
Transfs.
7 Days

Died

31

0 Gran.

42

Outcome

Transfs.
Pentnucle.

1000

M tar' last dose

4000

1

Male

Treatment

TABLE III
Tabulation of Reported Cases of
Granulocytopenia and Agranulocytosis
Reference

Diagp_o_sis

Sex
Age

Jennings
SouthwellSander

Ulcerative
Colitis

Female

Young

Rheumatism

39
Ma.le

53

Total
Drug

Total
Days

Onset of
. Di~_gl'.).Osis

94 gms.
Sulfa.n,

21

After last

54 gms.
Pront. Alb.

18

3 Days
After la.st dose

~-

..~

3 Days

"#\
"

..::-

..::..

·:t-

dose

Lowest
W.B.C.

Treatment

4lt4

Recovery

O Gran.

1800
O

Gran.

Outcome

Pentnucle.

Died

of this condition.

This is

suc·~est3d

since in the

4o ca:: es li;:Jtsd in Table III, 26 are fe:ualss and 15
D.re mu.les.

Two cas·::;s are not

li~Jted

.·,::ts to sex.

Possible etiological factors considered

~hich

may play a part in the develOJ)ment of' the:=; af;ranulocytopenia are bone marrov; da"«1age "by previous infection, bone
t1arrow chc::.nP:ed by cumulative affect of long continued
drug therapy, sex, abnormality of bone ::iarrovv of'
obscure

oriein, idiosyncrasy to drugs.

That various

factors may be concerned is evident, but the Iilechanism
of the production of this

abnor:~iali ty

reJ'iains unknown

as in the case of other druB idiosyncrasy.

A typical

geographical distribution is not apparent in the
case of t:'lis d.::.'uc idiosyncrasy because the -'-rug is so
universally used ·.inC! not conf'i:ied so closely to Germany,
United States, and Denmark as was the case with
a.rninopyrine.
and fro5 other

Ca . es are also reported fron }'ranee ( 79)
c~untries.

The class distribution also

does not hold for the sulfanilamide croup because it
is used for treating the infections of every class of
peo:i;:ile.
Pathology.

The pathology of' the bone inarrow

is reported in Table IV •

.As in aGranulocytosis associated

with other drugs, the findings vary.

-
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TABLE

r'1

Bresgen

Decrease in myeloid cells.
Increase in lynphocytes.

Dolgopol

Slight decrease in the nucleated cellular elements. Llost cells ic;:::ature.
Proninence of reticule-endothelial cells.
Ifony lymphocytes and megakaryocytes.

Pearson

Many mononuclear cells. J\Yo segmented
cells. Imrnature and developing
erythrocytes.

Sailor

Hyperplastic and aplastic changes.
Aplastic changes 'nere most marked.
areas of erythrocyte cle;:,truction.

Ho

Sheck et

:\Iyeloblastic arrest.

Schwartz,
et al.

Few mature neutrophils and erythrocytes.
Maturation arrest with stem cell hyperplasia. Reduction of nucleated red
cells accounted for the secondary
anemia.

Taub,
et al.

Hyperplasia 01· ster11 cells. Absence of
rnatu:Le cells oi· nyeloiu series.

Rosenthal,
et al.

A decrease in the total cell count -,·iith

Young

Bone raarrov1 aplasia.

a maturation arrest.

Course of Diseqse.

See Table III for infor-

nation concerning reports of ce.ses
penia and agranulocytosis.

01'

Th8 ono

sevGre

,c~r::inulocyto-

sy-;.-;~pto;:i e:~nd

associated nost often with this condition is
is an important warning signal of so

r~:::my

f'incJ_ing

feve~,

\Jhich

of the severe

toxic effect,.:; or the sulfanilamide crouv of drugs.

Fever

usually precedes skin eruptions, toxic hepatitis, as
well as acranulocytosis.

Other warni

signals which 2ay

or may not be an sie;n of beginning of this severe disturbance is a fever \1hich continues even thoue:h the symptoms
and sie,ns of the original infection have disappeared,
eruptions, c;radual but slow decrease in the hemoglobin,
and any abrupt rise or fall in the white blood count.
Table III is a tabulated record of available
case reports in the literature.
cases we

fin~

Fron a study of the

that in addition to the fever associated

with both the onset and the course of' the disease there
are chills, malaise, abdominal pains, sore throat, extrema
toxicity, weakness, headache, confusion, and a foul
breath.

'J;1here is always leukopenia with pro:f'ound e;ranu-

locytopenia which nay result in conTJlete disappearance
of all granulocytes.

There nay or nay not be angina.

The reports of cases cited from the table
indicate that the v'li tharawal of the urur, does not always
halt the progressive drop in white blood cells inITTediately
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but the counts often continue to drop 2 or 3 days after
the last dose.

The count may not :irop UYJ.til a few days

after ths last dose is given.

Often a

ste:~dy

but slow

decrease in the total white count vJi th no disturbance of
ratio of different cells is a sign of the beginnine of
the dyscrasia.

15 in males.

'l\venty-six cases occurred in females,
In two instances the sex is not stated.

There is no predominence of any age group.
type of infection predominates.

Ho single

The total nose of the

drug ranges from 14.5 to 100 grarns in a period of 7 to
39 days.

'Jith two exceptions the onset ranges fron1 14

to 21 days after the beginning of the <lrug's administration.

Sulfanilamide, sulfapyricline, and. pro:atosil had

been used in various instances.

Of the 43 reported cases,

le were fatal.

Treatr;ient.

Treatnent of '.Jhi te blood cell

dyscrasias associated with d.rugs of the sulfanila:r:i.ide
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froup is both prophylactic Gnd active.
The best vmy to avoid the development of
agranulocytosis associated

-c'.'i

tL the para-amino-benzene

sulf'onamide drue:;s woulcl be not to give the drug.
Since that is impossible because
able aids in saving

live~

thec~e

drugs are valu-

it is necessary that the

drug should not be given unless there exists an indication for its use.

Vll1en it is used, the course of' the

patient's illness should be carefully watched.

Fever,

rash, slowly progressing aneraia, slow response to
treatment, gradual decreasing Vlhite blood count with or
without neutropenia should all be regarded as warning
signals.

Other VJarning signals are development of

jaundice, and any abrupt rise or fall in white blood
cells.
Shecket and Price (93) say that if the efficacy
of one of these drugs in conbatting the infection is
not demonstrated from four to seven days after the
beginning of the administration, the drug should not be
continued, for they relieve

the prolonged administration

and the consequent large amounts of drug result in a
cumulative toxic effect.

Along this sa1:1e line of thought

is Bresgen's (9) advice to give large doses of the drug
for a short time and therebye avoid the long continued
effect of the drug upon the myeloid elements.
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He also

says that too small inadequate doses do not stop the
infection but keep up a chronic low grade type of
infection which results in added strain upon the bone
marrow along with the effect of the drug.

Shecket and

Price (93) also remind us that the fact that the drug
has been discontinued does not absolve us from co!1tinuing to watch the patient carefully, for often the
agranulocytosis does not shov1 itself until several
days after the last dose of the drug. (96)
If there is already depressed or a changed
bone n;arrow due to the nature of· an infectious disease
or other toxic factors, the question of' w'ether or not

to administe1· sulfanilamide should be carefully considered.
Carr and Hoot ( 14) advise that the J)hysician
and nursing staff be very watchful as long as the
patient is on the drug, but especiA.lly so after 14 days
have elapsed and the patient continues to receive it.
'.'ihenever a white count has been reduced to 3000 or
4000 the drug should be O.iscontinued irnnediately and the
patient carefully vmtched. (84)
cessation of the drug

tt~ereapy

Hohmann (41) advises
whenever the granulocytes

are decreased even thoueh the total white count has not
decreased.
After having considered the various suggestions
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made which are all valuable in the prevention of serious
blooG dyscrasias, it is evident that it is very foolish
to prescribe these drugs for every ache and pain.

At

this tillie the indications for the use of these drugs
are well established both by clinical investieation and
experience as \Nell as by experimental work, anO. the medical

profession contributes most to prophylaxis of severe

toxic effects upon the blood by not using the drug
ill-advisedly.
If agranulocytosis has occurred during or
bunediately following the ingestion of the sulfanilamide
group of drugs, the drue must be discontinued at once
if not already done.

Elimination from the body is

aided by forcing fluids. (68)(95)
Anemia is usually not associated with
agranulocytosis.

Blood transfusions shonld be made if

anemia is part of the picture.

rrhe transfusions' how-

ever, do not stimulate the bone

~La:c-row

and the relc:_tively

few leukocytes added to the circulation are of little or
no help for they are rapidly used.

X-Ray over the long

bones has been suggested to depress the bone marrow but
this has been abandoned as well as the theory that if
sepsis or necrosis is inducec1 the_:: need :Cor leukocytes
will sti1aulate their production or maturation.(27) (L1.r:3) (44)
Doan (23) says that nucleic acid exerts a
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chemotactic ef:::'ect upon nornal nyeloicl foci and
causes a pror.1r)t effective ir1crease in the deli very of
leu....~ocytes

to the

peri}Jhe1~a1

vascular systea.

Ee does

not believe that spont&neous recovery occurs from
agranulocytosis because he thinks it is due to an
intrinsic deficiency phenomenon.

The nucleic acid and

nucleotides supply the :3timulus of maturation and the
stinmluc-J of initiation of developnent

01'

leukocytes if the bone marroY1 is in a

co~1di t

pond. (80)(81)

cells to mature
ion to res-

If the condition has proeressed to such

a stage that the marrow has becofile aplastic, it will be
ir.irossible for it to be stimulated by any i1roducts of
nucleic acid.

IIall \35) sue;gests yell011 bone marrow

extract, because it supposedly supplies the intrinsic
factor vJhich is able to cause the bone narrow to produce
ni::..ture cells and. d.elive::: them to blood..

Yellmv bone

marrow extr::::ct is given orally in capsules containing
3.5 grains.

:Fifty to one hundred capsules are given

daily until monocytes appear in the blood, and monocytes'
reappearance in the blood stream are said to be of
favorable prognostic significance.

If adenine sulfate

is used it is surge sted that 1 grarl' be given intramuscularly three times a day until an incrs:-,,se in
neutrophils begins.

Jackson (43) advises pentnucleatide,

10 cc. intravenously four tiBes a day.
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Ile has had very

good results vvith this substance.
l'ron the cases reviewed, the best routine
followed in treating agranulocytosis is to exclude the
drug inmiediately and hasten its rapid excretion.
Blood transfusion is necessary if the hemoglobin is
less than

60?~.

Since it is not known what type of

mechanism is responsible for the dyscrasia, it seems
that no harm is done by using some form of a nucleatide
or liver extract.

The diet should be cor:iplete and the

patient given good nursing care.
iiyperleukocytosis.
Before leaving the discussion of white blood
cell disturbances, a few reports of hyperleukocytosis
have been made.

Fitzhugh (27) and Alpert (2) have found

this condition to occur es·pecially associated v'ii th drug
fever and rash.

A similar reaction has been noticed

in laboratory animals.(64)
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1.

A review· of' the literature concerning the

disturbances of the erythrocytes and leukocytes of the
blood associated v1ith the aQ.7ninistration of para-aminobenzene sulfonamide and its derivatives has been made.
2.

Both a chronic slowly-developir:..g hemolytic

anemia and an acute hemolytic anemia are occasio11ally
associated vlith the administration of these drues.
3.

Agranulocytosis and leucopenia are also

associated with the ingestion of these drugs.
4.

These hematological dyscrasias are very

similar to the sensitivity reactions caused by aminopyrine and other drugs of the amino benzene group of
drugs.
5.

Possible etiological factors which may be

concerned in the development of these types of drug
idiosyncrasy are size of the dose of the drug, the
length of' time the drug is e;iven, the sex: of the
patient, the effect of the infectious process which is
beine; tested, nnd the cumulative effect of the drug.

-
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6.

The actual mechanism of the production of

the anemia is not known, nor is the aechanism. of the
production of agranulocytosis understood.
l.!_

There is no typical characteristic bone

marrow picture associated vd th these conditions.
~

The promiscuous use of the drugs of the

para-amino-benzene sulf onarnide group is to be discouraged.

This applies to the medical profession as well

as to the laymen.
9.

1fuenever the drug has been prescribed for

a patient, the patient should be closely observed
during the course of the drug therapy.

If the

response is not favorable, the drug should not be
continued ove:::· too long a period of ti111e.

* * * * * *
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